NCT05470036Completed
Improving Germline Testing in At-Risk Patients With Prostate Cancer
IMPRINT: A Pilot Study to Improve Germline Testing in At-Risk Patients With Prostate Cancer
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational session.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 17 Jul 2022
- Start date
- 27 Sept 2022
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- University of California, San Diego
- Diseases
- Prostate cancer
- NCT number
- NCT05470036
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 27 Sept 2022 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had prior germline testing.
Other
- Have somatic genetic testing that is positive for a possible germline variant.
Who the study is looking for
- Men, age greater than or equal to 18 years of age.
- Diagnosis of prostate cancer of any histology.
- Must meet NCCN guidelines for germline testing
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Diego Coordinator of this site? Confirm its status | La Jolla | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.